Industry top-down
Drug Manufacturers - General
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
Overall, sales growth trends across the pharmaceutical industry were mixed. While some companies recorded robust sales growth, many faced sales declines or stagnation. EPS, a key profitability metric, also showed varying trends across companies. Some companies saw EPS decline despite increased sales, while others managed to grow EPS even with a slight decrease in sales. This suggests significant disparities in company performance within the industry.
- Mixed revenue growth across companies
- Divergent trends in profitability metrics (EPS)
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| ABBVAbbVie Inc. | FY2026 Q1 | $13.34B | +8.4% | $0.72 | -6.5% | — |
| MRKMerck & Co., Inc. | FY2026 Q1 | $15.53B | -1.6% | $2.01 | +7.5% | — |
| AMGNAMGEN INC | FY2026 Q1 | $8.15B | +9.4% | $3.20 | — | — |
| GILDGILEAD SCIENCES, INC. | FY2026 Q1 | $6.67B | -0.3% | $1.04 | — | — |
| PFEPFIZER INC | FY2026 Q1 | $13.72B | -7.8% | $0.52 | -5.5% | — |
| BMYBRISTOL MYERS SQUIBB CO | FY2026 Q1 | $11.2B | -5.6% | $1.20 | — | — |
| BIIBBIOGEN INC. | FY2026 Q1 | $2.43B | +6.1% | $1.64 | -39.3% | — |
| OGNOrganon & Co. | FY2026 Q1 | $1.51B | -6.7% | $0.33 | -57.7% | — |
| AMRNAMARIN CORP PLCUK | FY2026 Q1 | $42.02M | -25.7% | $-0.04 | — | — |
| 464280TDSPHARM Co., Ltd. | FY2026 Q2 | ₩8.08B | +44.7% | ₩181.00 | +11.7% | — |
| 118000METACARE Co., Ltd. | FY2026 Q2 | ₩8.76B | +52.1% | ₩23.00 | +27.8% | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).